Answers are grounded in this paper and cite their sources.
Age-related osteoporosis is characterized by progressive loss of bone mass and deterioration of trabecular microarchitecture, driven by chronic inflammation, redox imbalance, mitochondrial dysfunction, and osteoblast senescence that uncouples bone formation from resorption. During aging, declining nicotinamide adenine dinucleotide (NAD+) availability further exacerbates mitochondrial dysfunction and stress responses, suggesting that restoring NAD+ redox homeostasis could be a viable therapeutic strategy. Here, we reported a bifunctional nanozyme-mediated metabolic regulation strategy to promote NAD+ regeneration and scavenge reactive oxygen species (ROS) for the treatment of age-related osteoporosis. The bifunctional nanozyme (Pt/CeO2) was constructed by in situ growth of platinum nanoparticles on cerium oxide nanorods and was designed for ROS scavenging and NAD+ regeneration via NADH (reduced nicotinamide adenine dinucleotide) oxidation. In senescent osteoblasts, Pt/CeO2 reduced ROS, restored mitochondrial integrity, and alleviated senescence, thereby promoting osteogenic differentiation. In vivo results confirmed that systemic administration of Pt/CeO2 preserved trabecular architecture and increased bone mineral density in naturally aged mice. These findings demonstrated that coupling ROS scavenging with the restoration of NAD+ redox homeostasis via Pt/CeO2 nanozyme provided a promising therapeutic strategy to counteract osteoblast senescence and slow the progression of age-related osteoporosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: